Medicenna Therapeutics (TSX:MDNA) 3-Year Book Growth Rate : -18.20% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics 3-Year Book Growth Rate?

Medicenna Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was C$0.27.

During the past 12 months, Medicenna Therapeutics's average Book Value per Share Growth Rate was -43.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was -18.20% per year. During the past 5 years, the average Book Value per Share Growth Rate was 40.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 9 years, the highest 3-Year average Book Value per Share Growth Rate of Medicenna Therapeutics was 100.80% per year. The lowest was -64.70% per year. And the median was 11.50% per year.

Competitive Comparison of Medicenna Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Medicenna Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicenna Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's 3-Year Book Growth Rate falls into.

Medicenna Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Medicenna Therapeutics (TSX:MDNA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Medicenna Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines